User:Johncartmell/sandbox

Cyprotex Discovery Ltd
Company type	Public
Industry	Pharmaceutical & Biotechnology
Founded	1991
Headquarters	Macclesfield,UK
Products	Cloe SCREEN ; Cloe PK ; Cloe HIA
Website	www.cyprotex.com

Cyprotex is a preclinical discovery/development contract research organisation with a core focus in measuring and analysing the ADME (absorption, distribution, metabolism and excretion) and pharmacokinetic properties of potential new drugs. It is a specialist provider of in vitro ADME screening as well as in silico methods used in the prediction of in vivo pharmacokinetics.

Background

Cyprotex were originally founded by David Leahy in 1999; the objective was to create a company that would transform the ADME screening and pharmacokinetic prediction aspects of drug discovery by investment in the automation of workflow and decision making and a multidisciplinary approach to the delivery of science.

The company name was taken from a family of enzymes - the CYP450s.

Cyprotex moved to their current premises in Macclesfield in 2001, where their laboratories are housed. They achieved listing on the Alternative Investment Market of the London Stock Exchange in 2002.

Products

Cyprotex has developed a suite of services and technologies known as Cloe (Cyprotex Lead Optimisation Engine) which takes its name from the lead optimisation stage of the drug discovery process.

Research and development

Cyprotex have extensively researched and developed models for the prediction of in vivo plasma levels (PK) of xenobiotics from measured ADME properties using physiological based pharmacokinetic(PBPK) modelling techniques ^[1] ^[2] and models for the prediction of human intestinal absorption (HIA) ^[3]. This research has been developed into online services Cloe PK and Cloe HIA, respectively.

They have also developed an integrated and automated system for QSAR modelling for which they coined the term 'Discovery Bus' ^[4]

References

^ Leahy, D (2006). "Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models". Expert Opinion on Drug Metabolism & Toxicology. 2 (4): 619–628. doi:10.1517/17425255.2.4.619.
^ F. Brightman,F.A.;Leahy,D.E.; Searle,G.E.; and Thomas,S. (2005). "Application of a generic physiologically-based pharmacokinetic model to the estimation of xenobiotic levels in human plasma". Drug Metab. Dispos. 34 (1): 94–101. {{cite journal}}: Unknown parameter |pmi= ignored (help)CS1 maint: multiple names: authors list (link)
^ Metcalfe, Paul D and Thomas, Simon (2010). "Challenges in the prediction and modelling of oral absorption and bioavailability". Curr. Opin Drug Disc. Dev. 13 (1): 104–110.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Cartmell, J; Enoch,S.; Krstajic,D.; and Leahy, D (2005). "Automated QSPR through Competitive Workflow". J. Comput. Aided Mol. Des. 19 (11): 821–833. doi:10.1007/s10822-005-9029-8.{{cite journal}}: CS1 maint: multiple names: authors list (link)

External links

[1] Leahy, D (2006). "Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models". Expert Opinion on Drug Metabolism & Toxicology. 2 (4): 619–628. doi:10.1517/17425255.2.4.619.

[2] F. Brightman,F.A.;Leahy,D.E.; Searle,G.E.; and Thomas,S. (2005). "Application of a generic physiologically-based pharmacokinetic model to the estimation of xenobiotic levels in human plasma". Drug Metab. Dispos. 34 (1): 94–101. {{cite journal}}: Unknown parameter |pmi= ignored (help)CS1 maint: multiple names: authors list (link)

[3] Metcalfe, Paul D and Thomas, Simon (2010). "Challenges in the prediction and modelling of oral absorption and bioavailability". Curr. Opin Drug Disc. Dev. 13 (1): 104–110.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[4] Cartmell, J; Enoch,S.; Krstajic,D.; and Leahy, D (2005). "Automated QSPR through Competitive Workflow". J. Comput. Aided Mol. Des. 19 (11): 821–833. doi:10.1007/s10822-005-9029-8.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]

[4]